Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

bortezomib injection 1 MG and 2.5 MG VIAL Principal Display Panel (bortezomib for injection)

PRINCIPAL DISPLAY PANEL - 2.5 mg Vial Label

NDC 0409-1703-01

Bortezomib
for Injection

2.5 mg/vial

SINGLE-DOSE VIAL
DISCARD UNUSED PORTION

FOR INTRAVENOUS OR
SUBCUTANEOUS USE

Rx ONLY
CAUTION: Hazardous Agent
Hospira
CONTENTS: Lyophilized vial contains 2.5 mg
bortezomib and 25 mg mannitol.
Recommended Dosage: See Prescribing
Information.

PRINCIPAL DISPLAY PANEL - 2.5 mg Vial Label

PRINCIPAL DISPLAY PANEL - 2.5 mg Vial Carton

1 x 2.5 mg Single-dose Vial
NDC 0409-1703-01

Bortezomib
for Injection

2.5 mg/vial

SINGLE-DOSE VIAL
DISCARD UNUSED PORTION

FOR INTRAVENOUS OR
SUBCUTANEOUS USE

See Reconstitution
Information on Back

CAUTION: Hazardous Agent

Hospira

PRINCIPAL DISPLAY PANEL - 2.5 mg Vial Carton

PRINCIPAL DISPLAY PANEL - 1 mg Vial Label

NDC 0409-1704-01

Bortezomib for Injection

1 mg/vial

SINGLE-DOSE VIAL
DISCARD UNUSED PORTION

FOR INTRAVENOUS OR SUBCUTANEOUS USE

Rx only
CAUTION: Hazardous Agent

Hospira

PRINCIPAL DISPLAY PANEL - 1 mg Vial Label

PRINCIPAL DISPLAY PANEL - 1 mg Vial Carton

1 x 1 mg Single-Dose Vial
NDC 0409-1704-01

Bortezomib
for Injection

1 mg/vial

SINGLE-DOSE VIAL
DISCARD UNUSED PORTION

FOR INTRAVENOUS OR
SUBCUTANEOUS USE

See Reconstitution
Information on Back

CAUTION: Hazardous Agent

Hospira

PRINCIPAL DISPLAY PANEL - 1 mg Vial Carton
Show All Hide All
Show All Hide All
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event
Pfizer Safety

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.